Ask AI
AKTi or PI3Ki in MBC
Interactive Decision Support Tool: Expert Guidance on Selecting AKT or PI3K Inhibitors in Patients With Metastatic Breast Cancer

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

European Learners: 0.25 EBAC® CE Credit

Released: April 22, 2026

Instructions

This Interactive Decision Support Tool provides treatment recommendations for patients with HR-positive/HER2-negative metastatic breast cancer from 5 experts based on the specific patient and disease characteristics you enter in the tool. It is recommended that you have as much information as possible available before you begin.

You will be prompted to provide specific information about your patient including disease stage, previous therapy and duration of response to previous therapy, ET resistance status (primary vs secondary), and the presence of actionable biomarkers including ESR1, PIK3CA, AKT, PTEN, and BRCA genetic alterations.

Click on your selections. Your choices can be changed at any time simply by selecting the [change] icon by the question you want to change and entering a new choice.

Additional information on each variable/characteristic and why it is important for making management decisions is available by clicking on the [i] icon after each selection.

When all patient characteristics are entered, you will be asked to select the management option you are currently planning. Once that information is entered, you can click on Submit Patient Case to view the expert recommendations.

After reviewing your case-specific recommendations, you will be asked brief questions about how the recommendations influenced your decision-making. You will then be able to enter a new case scenario by clicking the Start New Case button.

When viewing the tool on the Decera Clinical Education website, you will also have the following options:

  • Print/download the recommendations along with a summary of the patient characteristics and selected therapy you entered by clicking the Case Summary button

Note: The current tool was developed in April 2026 and reflects the expert recommendations at that time.

Access to and use of this Interactive Decision Support Tool titled, “Interactive Decision Support Tool: Expert Guidance on Selecting AKT or PI3K Inhibitors in Patients With Metastatic Breast Cancer” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal treatment selection for patients with HR-positive locally advanced/recurrent or metastatic breast cancer. The information provided in the tool is based on the latest guidelines, indications, and expert guidance of Francois-Clement Bidard, MD, PhD; Giampaolo Bianchini, MD; Nadia Harbeck, MD; Cristina Saura Manich, MD, PhD; and Peter Schmid, MD, PhD, FRCP. The material published by Decera Clinical Education reflects the views of the reviewers or authors of the Decera Clinical Education material, not those of Decera Clinical Education, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in “Interactive Decision Support Tool: Expert Guidance on Selecting AKT or PI3K Inhibitors in Patients With Metastatic Breast Cancer” has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Decera Clinical Education provides this information on an as-is basis. This disclaimer applies to all material published by Decera Clinical Education, including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

©2026 Decera Clinical Education, LLC. All rights reserved.

Program Content